PO.MCB10.01 · 分子与细胞生物学

miR-342-5p:弥漫性胸膜间皮瘤中一个有前景的抑癌基因

miR-342-5p: A promising tumor suppressor in diffuse pleural mesothelioma

海报缩略图:miR-342-5p:弥漫性胸膜间皮瘤中一个有前景的抑癌基因
编号 2052 展板 12 时间 4/20 09:00–12:00 区域 Section 25 主讲 So Hyun Yoon, MS;PhD
分会场 MicroRNAs as Cancer Biomarkers, Therapeutic Targets, and Modulators of Treatment Response
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

So-Hyun Yoon, Anand Singh, Nathanael Pruett, Vivek Singh, Smrity Sahu, Yelixza Avila, Chuong Hoang

NIH-NCI, Bethesda, MD

摘要 Abstract

中文摘要
弥漫性胸膜间皮瘤(DPM)是一种无法治愈、侵袭性强的肿瘤,治疗手段有限。超越传统方法,我们认为microRNA(miRNA)——即协同调控基因表达的短的非编码RNA——能够独特地破坏DPM中涉及的分子网络。在本研究中,我们将miR-342-5p确定为一种新的DPM相关miRNA。我们使用人miRNA模拟物文库,在一组DPM细胞系上筛选具有抗增殖作用的miRNA。在最有效的候选中就有miR-342-5p。我们分析了DPM患者标本相比正常胸膜中miR-342-5p的下调情况(正常=22,肿瘤=50)。TCGA-MESO分析显示,miR-342-5p下调与不良生存结局显著相关。我们的结果表明,重新表达miR-342-5p显著损害了DPM细胞活力,减少了2D集落灶形成,并抑制了软琼脂和球体实验中的非锚定依赖性细胞生长。此外,Annexin-V实验显示,与对照相比,转染miR-342-5p的DPM细胞中早期和晚期凋亡细胞显著增加。而且,我们通过PARP裂解和caspase-3/7的激活确认了miR-342-5p处理的DPM细胞中凋亡的诱导。重要的是,当用miR-342-5p处理正常人间皮细胞(NP1系)时,未观察到显著的生物学效应。接下来,我们进行了生物素-miRNA(Bi-miR)下拉实验,这是一种直接结合实验,其中生物素标记的miR-342-5p探针在混合裂解液中捕获其相关的mRNA转录本。然后进行RNA-seq分析,以识别DPM中与凋亡和细胞死亡通路相关的直接靶基因。我们识别出被miR-342-5p靶向且同样参与其在DPM中抑癌活性的顶级转录本。总体而言,我们的发现凸显了miR-342-5p的抑癌作用及其用于DPM治疗的治疗潜力。
查看英文原文 English abstract
Diffuse pleural mesothelioma (DPM) is an incurable, aggressive neoplasm with limited therapies. Moving beyond conventional approaches, we posit that microRNAs (miRNA), short, non-coding RNA that coherently regulate gene expression, can uniquely disrupt the molecular networks involved in DPM. In this study, we identified miR-342-5p as a novel DPM-associated miRNA. We used a human miRNA mimic library to screen for miRNAs with antiproliferative effects on a panel of DPM cell lines. Among the most potent candidates was miR-342-5p. We profiled the downregulation of miR-342-5p in DPM patient specimens compared to normal pleura (Normal=22, Tumor=50). TCGA-MESO analysis revealed that miR-342-5p downregulation is significantly associated with poor survival outcomes. Our results demonstrated that the re-expression of miR-342-5p significantly impaired DPM cell viability, reduced 2D colony foci formation, and inhibited anchorage-independent cell growth in soft-agar and sphere assays. Additionally, Annexin-V assays showed a significant increase in early and late apoptotic cells in miR-342-5p transfected DPM cells compared to controls. Furthermore, we confirmed the induction of apoptosis in miR-342-5p-treated DPM cells through PARP cleavage and the activation of caspase-3/7. Importantly, no significant biological effects were observed when normal human mesothelial cells (NP1 line) were treated with miR-342-5p. Next, we performed a Biotin-miRNA (Bi-miR) pull-down assay, a direct binding assay in which a biotin-tagged miR-342-5p probe captures its associated mRNA transcripts in a pooled lysate. Then, RNA-seq analysis is conducted to identify direct target genes associated with apoptosis and cell death pathways in DPM. We identified the top transcripts targeted by miR-342-5p that are also involved in its tumor-suppressive activity in DPM. Overall, our findings highlight the tumor suppressive effects and therapeutic potential of miR-342-5p for DPM treatment.
利益披露 Disclosure
S. Yoon, None.. A. Singh, None.. N. Pruett, None.. V. Singh, None.. S. Sahu, None.. Y. Avila, None.. C. Hoang, None.

← 返回 AACR 2026 检索